Skip to main content

Table 1 Summary of efficacy and adverse event outcomes in duloxetine trials

From: Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials

   Number of Percent with   
Outcome Dose (daily maximum) Trials Patients Duloxetine Placebo Relative benefit or risk (95% CI) NNT/NNTp/NNH(95% CI)
Efficacy
50% PR All 20/60/120 mg 6 2,216 41 24 1.7 (1.4 to 1.9) 5.9 (4.8 to 7.7)
50% PR PDN 60/120 mg 3 1,024 47 27 1.7 (1.4 to 2.1) 5.1 (3.9 to 7.3)
50% PR fibromyalgia 60/120 mg 3 996 37 21 1.7 (1.4 to 2.1) 6.4 (4.7 to 9.9)
50% PR 60 mg 5 1,211 43 26 1.7 (1.4 to 2.0) 5.8 (4.4 to 8.4)
50% PR 120 mg 6 1,410 42 24 1.7 (1.5 to 2.0) 5.7 (4.5 to 7.8)
Adverse events general
Withdrawal – all cause 20/60/120 mg 6 2,418 30 26 1.2 (1.1 to 1.4) 26 (13 to 426)
Withdrawal – LoE 20/60/120 mg 5 1,872 4 9 0.5 (0.4 to 0.7) 20 (13 to 42)
Withdrawal – AE 20/60/120 mg 6 2,220 15 8 1.8 (1.4 to 2.4) 15 (11 to 25)
Any AE 60/120 mg 4 1,243 82 67 1.2 (1.2 to 1.3) 6.7 (5.0 to 10)
Serious AE 60/120 mg 3 1,034 2 3 0.8 (0.4 to 1.7) not calculated
Specific adverse events
Nausea 20/60/120 mg 3 1,145 29 10 3.0 (2.2 to 4.3) 5.3 (4.3 to 6.9)
Somnolence 20/60/120 mg 3 1,145 14 4 2.9 (1.7 to 4.9) 11 (8.0 to 16)
Constipation 20/60/120 mg 3 1,145 13 3 3.6 (2.0 to 6.5) 11 (8.3 to 16)
Decreased appetite 20/60/120 mg 2 811 7 1 4.9 (1.7 to 14) 18 (12 to 34)
  1. PR – pain relief; PDN – painful diabetic neuropathy; LoE – lack of efficacy; AE – adverse event
  2. In the right hand column, bold font is used for NNT – number needed to treat; normal font for NNTp – number need to treat to prevent; italic font for NNH – number needed to harm